Company news
Alumis Inc. news in 2025
Alumis Inc.'s news releases, calls and decks from 2025, newest first.
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 13, 2025
Alumis to Participate in Upcoming November Investor Conferences
November 4, 2025
Alumis to Participate in Upcoming September Investor Conferences
August 29, 2025
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
July 24, 2025
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
July 14, 2025
Alumis to Present at the Jefferies Global Healthcare Investor Conference
May 29, 2025
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
May 29, 2025
Alumis Completes Merger with ACELYRIN
May 21, 2025
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 14, 2025
Alumis Stockholders Approve Merger with ACELYRIN
May 13, 2025
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 12, 2025
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 1, 2025
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
April 4, 2025
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
March 25, 2025
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 19, 2025
Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 10, 2025
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
March 8, 2025
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
March 4, 2025
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 4, 2025
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
February 27, 2025
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 19, 2025
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 9, 2025
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 5, 2025
Alumis Strengthens Leadership Team with Key Appointments
January 27, 2025
Decks in 2025
- ASOPRS 2025
Conference · 14 slides · Sep 26, 2025
- Investor Presentation (September 2025)
Investor deck · 45 slides · Sep 3, 2025
- Jefferies Global Healthcare Conference 2025
Conference · 27 slides · June 2025
- Merger or Acquisition (March 2025)
Merger or acquisition · 10 slides · Mar 18, 2025
- Technical Presentation (March 2025)
Technical · 14 slides · Mar 10, 2025
- Merger or Acquisition (February 2025)
Merger or acquisition · 18 slides · Feb 6, 2025